Title for MeetingAbstracts
Alphabetical listing of titles
Oral mycoplasma and Candida from HIV infected (+) non-AIDS subjects.
Oral natural low-dose human alpha-interferon (HuIFN) in 30 patients with human-immundeficiency-virus (HIV-1) infection. A double-blind randomized placebo-controlled clinical trial.
Oral non-Hodgkin's lymphoma (ONHL) in 7 HIV-positive homosexual males.
Oral nutritional support in HIV-infected patients: clinical and laboratorial study.
Oral Oseltamivir Prevents the Spread of Influenza Between Children in Households.
Oral Oseltamivir Rapidly Delivers Active Drug Levels to Middle Ear and Sinuses in Humans.
Oral Oseltamivir Reduces the Risk of Developing Acute Otitis Media Following Influenza Infection in Children.
Oral pathologies observed in HIV-positive children in Venezuela.
Oral pathology (OP) in a seroincident cohort.
Oral pathology (OP) in a seroincident cohort: early appearance of erythematous candidiasis.
Oral pathology in 105 HIV-reactive patients in Buenos Aires.
Oral pathology in HIV infected patient.
Oral pathology in pediatric HIV+ patients in Argentina.
Oral pathology in pediatric patients with HIV infection.
Oral pathology is a good predictor for HIV infection in high risk population.
Oral PMPA prodrug: relationship between clinical pharmacokinetics, safety and anti-HIV activity.
Oral protein calorie supplements for children with chronic disease: Lack of evidence for a costly intervention.
Oral Recombinant Beta-Lactamase Treatment Prevents Piperacillin-Induced Intestinal Overgrowth of Nosocomial Pathogens in Mice.
Oral retarded morphine in pain management in HIV patients.
Oral sex and barrier use among HIV infected and at risk uninfected women reporting recent sexual contact with a woman.
Oral sex and HIV transmission: a survey on line.
Oral sex: calculating the real risks.
Oral shedding of CMV and HSV in relation to HIV disease.
Oral SIV infection in adult and neonatal macaques.
Oral squamous cell carcinomas in HIV infection.
Oral Telithromycin (HMR 3647; 800mg OD) for 5 Days and 10 Days is Well Tolerated and as Effective as Amoxicillin/Clavulanic Acid (500/125mg TID) for 10 Days in Acute Maxillary Sinusitis (AMS) in Adults.
Oral Telithromycin (HMR 3647; 800mg od) for 5 Days is Well Tolerated and as Effective as Cefuroxime Axetil (500mg Bid) for 10 Days in Adults with Acute Exacerbations of Chronic Bronchitis (AECB).
Oral Telithromycin (HMR 3647; 800mg OD) for 5 Days is Well Tolerated and as Effective as Clarithromycin (250mg BID) for 10 Days in Group A b-Hemolytic Streptococcal Pharyngitis/Tonsillitis.
Oral Telithromycin (HMR 3647; 800mg OD) for 7-10 Days is Well Tolerated and as Effective as Oral Trovafloxacin (200mg OD) for 7-10 Days in Community-Acquired Pneumonia (CAP) in Adults.